Actively Recruiting
Randomized, Double-Blind Study of Daily EVO756 Doses Versus Placebo for Migraine Prevention in Adults
Led by Evommune, Inc. · Updated on 2026-11-04
330
Participants Needed
45
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating EVO756, a medication taken orally, to study its effects on adults with migraine. This phase 2 trial aims to test the efficacy and safety of two different daily doses of EVO756 compared to a placebo. The study focuses on preventing migraines and is sponsored by Evommune, Inc. Participants will be randomly assigned to one of three groups one receiving daily Dose 1 of EVO756, another receiving daily Dose 2 of EVO756, or a placebo group taking a daily placebo pill. The treatment period lasts 12 weeks, during which participants take their assigned medication every day. Throughout the study, participants will have regular assessments to track changes in the number of monthly migraine and headache days, medication use, and any side effects. The main measurement is the change in monthly migraine days during the last month of treatment. Safety monitoring continues through week 16. The overall study runs from July 2026 to November 2027, with participants involved for at least 12 weeks of treatment and follow-up.
CONDITIONS
Brief Title
Study of EVO756 in Adults With Migraine
Research Team
N
Nichole Baio
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here